Is OPKO Health (OPK) A Bargain As New Results And Guidance Reset Valuation?
How Investors May Respond To OPKO Health (OPK) Updated Revenue Guidance
OPKO Health (OPK) Q3 2026 Earnings Call Transcript
What OPKO Health (OPK) Said on Its Q3 Earnings Call
OPKO Health Inc (OPK) (Q3 2026) Earnings Call Highlights: Revenue Climbs 16% as LabCorp Deal ...
OPKO Health, Inc. (OPK) Q3 2026 Earnings Call Transcript
OPKO Health (OPK) Reports Q3 Loss, Misses Revenue Estimates
OPKO Health: Q3 Earnings Snapshot
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
CORRECTION: OPKO Health Q3 EPS $(0.05) Beats $(0.06) Estimate, Sales $65.400M Miss $141.267M Estimate
OPKO Health FY2026 Sales from continuing operations of Guidance of $268.000M-$278.000M
OPKO Health Sees Q4 Sales $62.000M-$72.000M
OPKO Health Q3 2026 Earnings Call Transcript
OPKO Health (OPK) Stock Looks Pricey As Focus Turns To Its 58% Five Year Fall
OPKO Health to Report Third Quarter 2026 Financial Results on November 4, 2026
OPKO Health’s OPKO Biologics Doses First Participant in Phase 1/2a Trial of OPK-8801001 for Acromegaly
OPKO Biologics Doses First Patient In Its Phase 1/2a Clinical Study Of OPK-8801001 To Treat Acromegaly
OPKO Health (OPK) Sells BioReference Assets On A Valuation Story That Still Divides
Is OPKO Health (OPK) Pricing In Too Much For Sales?
Piper Sandler Reiterates Overweight on OPKO Health, Raises Price Target to $4
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.